FLT3 Inhibitors in the Therapy of Acute Myeloid Leukemia

Characteristics and outcomes of patients with AML and FLT3-TKD mutationsПодробнее

Improving treatment approaches for FLT3-mutated AML: insights into the Optimise-FLT3 trialПодробнее

Addressing Current Questions and Controversies in the Management of Acute Myeloid LeukemiaПодробнее

Adding a FLT3 Inhibitor May Improve Chemo Efficacy for Newly Diagnosed AML | Musa Yilmaz, MD| #ASH24Подробнее

Long-term survival and relapse patterns in FLT3-mutated AML treated with frontline triplet therapyПодробнее

Unlocking FLT3 Mutations in AML TreatmentПодробнее

FLT3 inhibitors: revolutionizing the management of AMLПодробнее

The use of gilteritinib in post-transplant maintenance for AML with FLT3-ITDПодробнее

Updates on the FLT3 inhibitor FF-10101 for the treatment of R/R AMLПодробнее

Continuous treatment with FLT3 inhibitors for patients with FLT3-mutated AML undergoing alloSCTПодробнее

Mechanisms of resistance to FLT3 inhibitors in AML and strategies to overcome thisПодробнее

Current research into post-alloSCT maintenance therapy in AMLПодробнее

MRD to identify those who benefit the most from FLT3 inhibition with gilteritinib in CR1 of AMLПодробнее

Targeted therapies in AML: menin, FLT3 and IDH inhibitorsПодробнее

Second-generation FLT3 inhibitors in the treatment of FLT3-ITD AMLПодробнее

Azacitidine and venetoclax plus gilteritinib in the treatment of FLT3-mutated AMLПодробнее

Prognostic signature for FLT3-like wild type AMLПодробнее

Personalizing AML treatment by targeting MRD mutationsПодробнее

Ep 3 : The Rationale for More Potent FLT3 Inhibitors for Acute Myeloid Leukemia – Enter QuizatinibПодробнее

Ep 4 : FLT3 Treatment-Related Adverse Events in Patients with Acute Myeloid LeukemiaПодробнее